Novel Molecular Targets for Mood Disorders and Psychosis Proceedings of a Workshop (2021) / Chapter Skim
Currently Skimming:
2 Current Drug Development Landscape and Limitations of Molecular Targets for Mood Disorders and Psychosis
2 Current Drug Development Landscape and Limitations of Molecular Targets for Mood Disorders and Psychosis
Pages 5-12
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 5... ...
Eventually, rational drug discovery led to the development of fluoxetine (Prozac) and other selective serotonin reuptake compounds (Paul)
|
From page 6... ...
The current generation of drugs does provide modest benefits over earlier formulations when they do work, Paul acknowledged, but many patients show no responses at all. In addition, most antidepressants have a delayed onset of action and troubling side effects, leading to reduced adherence; these drugs also carry black box warnings for suicidal ideation in adolescents, he said.
|
From page 7... ...
Today, he teaches and performs psychiatric mental health care as a nurse practitioner and serves on the board of directors for NAMI. Larrauri also described how he has recently decided to attend law school at the University of Michigan to pursue his goal of mental health care policy reform and advocacy.
|
From page 8... ...
She described receiving her college acceptance letters while in the hospital, and recalled needing to get permission from the hospital to leave the site to attend her high school graduation. In time, her health care team identified effective medications to treat the depression and enable her to attend college.
|
From page 9... ...
A colleague and friend referred her to Gerard Sanacora, professor and director of the Yale Research Depression Program and an expert on ketamine and mood disorders. Through Sanacora, she was able to enroll in a Phase 2 clinical trial testing the antidepressant efficacy of different doses of ketamine administered as a single intravenous infusion.
|
From page 10... ...
, a derivative of the phenothiazine antihistamine promethazine, did indeed reduce stress during surgery without producing marked sedation. Psychiatrists Jean Delay and Pierre Deniker subsequently showed that in manic patients, Thorazine also displayed antipsychotic effects, separate from its sedative properties and unrelated to histamine.
|
From page 11... ...
, said Paul. By 1993, he said, Prozac was prescribed to nearly five million patients in the United States and gave rise to the development of many other selec tive serotonin reuptake therapies that are now the standard of care for depression and other mood disorders.
|
From page 12... ...
UNMET NEEDS IN TREATING PSYCHIATRIC DISORDERS Although many antidepressant formulations have been available since the 1950s, depression continues to be a leading cause of disability, with a full 30 percent of people with major depressive disorder receiving little or no benefit despite treatment with multiple drugs, said Husseini Manji, global head at Johnson & Johnson Science for Minds. Even when currently available antidepressants work, they often have a slow onset of action, said Manji.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.